Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer

Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer




Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer

An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes.


PARIS–(BUSINESS WIRE)–Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden.

Independent, Blinded Evaluation Using Phase III Trial Data

The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dx predictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified protocol and statistical analysis plan.

Within this clinically high-risk population, myStage Dx identified two groups with markedly different long-term outcomes. The Low Risk group comprised 23.5% of patients. At ten years, the estimated proportion alive and free from breast cancer recurrence was 96.1% in the Low Risk group, compared with 76.6% in the Not Low Risk group. The difference remained statistically significant after adjustment for standard clinicopathological prognostic factors. These findings build on earlier evidence from the CANTO and UNIRAD trial cohorts, published in the Journal of Clinical Oncology in 2025.

“Confidence in a clinical test has to be earned through independent scrutiny. We chose a blinded evaluation of myStage Dx by an independent research team, accepting that the results were outside our control. These findings are consistent with our previous studies and reinforce the test’s ability to address a concrete clinical problem: identifying patients with a favorable prognosis despite clinically high-risk disease, with a clear risk classification to inform treatment discussions,” says Dr. Marvin Lerousseau, co-founder and CSO of Spotlight Medical.

Refining Recurrence Risk Assessment to Support Clinical Decision-Making

Patients considered clinically high-risk may be eligible for additional treatment, including CDK4/6 inhibitors, yet their individual recurrence risks can vary substantially. In PANTHER, patients received chemotherapy and endocrine therapy without CDK4/6 inhibitors. By identifying a subgroup with favorable long-term outcomes under those treatment conditions, myStage Dx provides prognostic information to inform discussions about treatment strategy. These discussions should consider individual recurrence risk, the expected benefits and risks of additional treatment, and patient preferences, consistent with ASCO guidance.

“As ASCO guidelines highlight, accurately assessing recurrence risk is essential to treatment decisions. For patients, additional therapies can mean up to three more years of treatment, with side effects, anxiety, and a real impact on daily life. We are proud to show how myStage Dx can help oncologists better assess individual risk and support more informed clinical decisions, with the aim of improving patient care,” said Sylvain Berlemont, co-founder and CEO of Spotlight Medical.

About Spotlight Medical

Spotlight Medical is an oncology diagnostics company developing evidence-driven, clinical-grade AI tests to support more precise cancer care. The company combines routine pathology, clinical data and explainable AI to develop prognostic assays designed for practical adoption in oncology workflows.

About myStage Dx

myStage Dx is a software-only in vitro diagnostic medical device that has received CE marking under the European Union IVDR. It combines the analysis of a digitized histopathology slide with routinely available clinicopathological data to generate a prognostic classification intended for use by qualified healthcare professionals.

Contacts

Media
press@spotlightmedical.com
spotlightmedical.com | mystagedx.com

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5




BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5

SAN CARLOS, Calif.–(BUSINESS WIRE)–$ONC #BeOne–BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.


The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website.

About BeOne Medicines

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.

To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date hereof, and BeOne undertakes no duty to update such information unless required by law.

Contacts

Investor Contact:
Liza Heapes

Tel:+1 857-302-5663

ir@beonemed.com

Media Contact:
Kyle Blankenship

Tel:+1 667-351-5176

media@beonemed.com

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026




Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026

Highlights Include Phase II Data Supporting Clinical Development Expansion for Ivonescimab

MIAMI–(BUSINESS WIRE)–Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), taking place October 23-27, 2026, in Madrid, Spain.


Across 10 presentations at ESMO 2026, ivonescimab data will span a broad range of tumor types, led by positive overall survival findings from Akeso Inc.’s Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy compared to durvalumab plus chemotherapy in first-line advanced biliary tract cancer, which is selected as a Late-Breaking Abstract for the Presidential Symposium. HARMONi-GI1 is a multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusively generated, managed, and analyzed by Akeso. On October 21, Summit and ECOG-ACRIN Cancer Research Group announced the initiation of the open-label Phase II/III EA2251 study, which plans to enroll patients in the U.S. who will be randomized to receive ivonescimab in combination with gemcitabine and cisplatin, or pembrolizumab or durvalumab in combination with gemcitabine and cisplatin as the established standard-of-care comparator regimen. Activation of clinical trial sites is expected to begin in the fourth quarter of 2026.

Additional data include findings from investigator-sponsored trials (ISTs). A rapid oral presentation and a proffered paper will feature ivonescimab-based regimens in first-line recurrent/metastatic thymic carcinoma and advanced renal cell carcinoma, respectively. The program also highlights emerging endometrial cancer (EC) data, alongside continued development in gastrointestinal cancers such as esophageal, gastric/GEJ, and pancreatic cancers; glioblastoma; and head and neck squamous cell carcinoma.

In a Phase II study in EC conducted at Memorial Sloan Kettering Cancer Center in New York, NY, ivonescimab monotherapy met the study’s primary endpoint for objective response rate with a manageable safety profile without new safety signals in previously treated patients with second-line and later EC. The strength of these results supported expansion of the IST led by Drs. Maria Rubinstein, MD, and Vicky Makker, MD, and provided a meaningful signal to inform opportunities for further development of ivonescimab in EC.

“The breadth of the ivonescimab data at ESMO underscores the expanding body of clinical evidence across a diverse range of tumor types and treatment settings,” said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics. “Our ambition for ivonescimab extends beyond any single indication. We are focused on advancing a rigorous clinical development program to determine where this novel IO bispecific antibody could make a meaningful difference for patients. We look forward to engaging with the global oncology community on these data at ESMO 2026.”

The ESMO 2026 ivonescimab presentations are listed below by tumor type:

Biliary Tract Cancer

Presidential Symposium Presentation: Ivonescimab plus chemotherapy versus durvalumab plus chemotherapy as first-line treatment for advanced biliary tract cancer: a randomized, controlled, double-blinded, phase 3 trial (HARMONi-GI1)

Presidential Symposium II, Oct 25, 5:42-5:54 pm CET, Abstract #LBA8

Endometrial Cancer

Poster: A phase 2 study of ivonescimab (PD1/VEGF bispecific antibody) for the treatment of endometrial cancer (EC)

Abstract #1266P

Esophageal Squamous Cell Carcinoma

Poster: Ivonescimab (AK112) plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma: A phase 2 single-arm study

Abstract #2908P

Gastric and GEJ Adenocarcinoma

Poster: AK112 (PD-1/VEGF bispecific antibody) combined with low-dose radiotherapy and nab-paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma: A prospective, multicenter, phase II study

Abstract #2898P

Glioblastoma

Poster: Ivonescimab combined with dose-dense temozolomide in recurrent glioblastoma: Preliminary results of efficacy and safety from a single-arm, phase Ib/II trial

Abstract #706P

Head and Neck Squamous Cell Carcinoma

Poster: Ivonescimab combined with chemotherapy as first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma: A prospective, open-label, single-arm phase II study

Abstract #1676eTiP

Pancreatic Cancer

Poster: Neoadjuvant ivonescimab plus gemcitabine/nab-paclitaxel for borderline resectable pancreatic cancer: A prospective single-arm phase II trial

Abstract #3161P

Renal Cell Carcinoma

Oral Presentation: Efficacy and safety of AK112 (Ivonescimab), a PD-1/VEGF bispecific antibody, as first-line treatment for patients with IMDC favorable-risk advanced renal cell carcinoma (aRCC): Results from a phase Ib/II study

Proffered Paper 2 Session: Genitourinary Tumours, Renal and Urothelial; Oct 25, 9:32-9:42 am CET, Abstract #3592O

Thymic Carcinoma

Rapid Oral Presentation: Ivonescimab plus chemotherapy as first-line treatment in recurrent/metastatic thymic carcinoma: Results from the iTHYM phase II study

Rapid Oral Session: Non-metastatic NSCLC and Other Thoracic Malignancies; Oct 26, 11:07-11:12 am CET, Abstract #4156RO

Poster: Ivonescimab plus chemotherapy as first-line treatment for advanced thymic carcinoma: Preliminary results from a phase II study with dynamic biomarker exploration

Abstract #2020eP

Ivonescimab is an investigational therapy that is not approved by any regulatory authority in Summit’s license territories, including the United States and Europe. Ivonescimab was initially approved for marketing authorization in China in May 2024.

About Ivonescimab

Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF.

This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al, iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of ivonescimab’s design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets.

Ivonescimab was invented by Akeso Inc. (HKEX Code: 9926.HK) and is currently utilized in multiple Phase III clinical trials. Over 5,000 patients have been treated with ivonescimab in clinical studies globally and over 100,000 patients when considering those treated in a commercial setting in China, as noted by Akeso.

There are currently 17 Phase III clinical studies that are either announced, ongoing, or have been completed studying ivonescimab, five of which are Summit-sponsored global studies, two of which are studies sponsored by cooperative groups, and 10 of which are being or have been conducted in China by Akeso. Summit began its clinical development of ivonescimab in NSCLC and expanded its sponsored Phase III clinical development program into colorectal cancer (CRC) and urothelial carcinoma (bladder cancer).

About Summit Therapeutics Inc.

Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, physician-, caregiver- and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs.

Summit was founded in 2003 and the company’s shares are listed on the Nasdaq Global Market (symbol “SMMT”). Summit is headquartered in Miami, Florida, with additional offices in Palo Alto, California, Princeton, New Jersey, Dublin, Ireland, and Oxford, UK.

For more information, please visit https://www.smmttx.com and follow Summit on X @SMMT_TX.

Summit Forward-Looking Statements

Any statements in this press release about the Company’s future expectations, plans and prospects, including but not limited to, statements about the risk that the private placement does not close on the anticipated timeline or at all, including because required regulatory clearances are not obtained or other closing conditions are not satisfied, dilution to existing stockholders, and potential adverse effects on the market price of the Company’s common stock, including from future sales by AstraZeneca, the Company’s broad discretion over the use of proceeds, and the possibility that the proceeds will not be sufficient to fund operations as long as anticipated, AstraZeneca’s ownership and contractual rights, including Third Party acquisition participation, and registration rights, and potential conflicts of interest, the completion of the Private Placement does not depend on the parties entering into a definitive collaboration agreement, the Company’s reliance on AstraZeneca for the supply of AstraZeneca’s products and other contributions to the clinical trials, the clinical and preclinical development of the Company’s product candidates, entry into and actions related to the Company’s partnership with Akeso Inc. and other collaborations, the intended use of the net proceeds from the private placements, the Company’s anticipated spending and cash runway, the therapeutic potential of the Company’s product candidates, the potential commercialization of the Company’s product candidates, the timing of initiation, completion and availability of data from clinical trials, the potential submission of applications for marketing approvals, the expected timing of BLA submissions or FDA decisions, potential acquisitions, statements about the previously disclosed At-The-Market equity offering program (“ATM Program”), the expected proceeds and uses thereof, the Company’s estimates regarding stock-based compensation, and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the Company’s ability to sell shares of our common stock under the ATM Program, the conditions affecting the capital markets, general economic, industry, or political conditions, including the effects of geopolitical developments, domestic and foreign trade policies, and monetary policies, the results of our evaluation of the underlying data in connection with the development and commercialization activities for ivonescimab, the outcome of discussions with regulatory authorities, including the Food and Drug Administration, the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials, the results of such trials, and their success, global public health crises, that may affect timing and status of our clinical trials and operations, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials or preclinical studies will be indicative of the results of later clinical trials, whether business development opportunities to expand the Company’s pipeline of drug candidates, including without limitation, through potential acquisitions of, and/or collaborations with, other entities occur, expectations for regulatory approvals, laws and regulations affecting government contracts and funding awards, availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of filings that the Company makes with the Securities and Exchange Commission. Summit defines a “positive study” as a clinical study with one or more prespecified primary endpoints in which one of those endpoints achieves a statistically significant benefit according to the protocol or statistical analysis plan. Any change to our ongoing trials could cause delays, affect our future expenses, and add uncertainty to our commercialization efforts, as well as to affect the likelihood of the successful completion of clinical development of ivonescimab. Accordingly, readers should not place undue reliance on forward-looking statements or information. In addition, any forward-looking statements included in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company specifically disclaims any obligation to update any forward-looking statements included in this press release.

Summit Therapeutics and the Summit Therapeutics logo are registered trademarks of Summit Therapeutics Inc. and/or its affiliates. Copyright 2026, Summit Therapeutics Inc. All Rights Reserved.

Contacts

Summit Therapeutics’ Media & Investor Contacts:
Nathan LiaBraaten

Senior Director, Investor Relations

Tracy Jones

Director, Media & Public Relations

investors@smmttx.com
media@smmttx.com

Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease

Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease




Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease

Recruitment is expected to start this month, rolling out to upwards of 31 sites across nine EU countries, and joining the ongoing enrollment in the US and UK, with Canada set to follow

Prilenia and Ferrer will share new data analyses and clinical trial updates at the European Huntington’s Disease Network (EHDN) Clinical Research Congress

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain–(BUSINESS WIRE)–#HD—Prilenia Therapeutics B.V. and Ferreri today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington’s disease (HD) has received authorization to begin in participating EU Member States (clinicaltrialsregister.eu 2026-526093-16-00, clinicaltrials.gov NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow.


Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life.

“The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to build on learnings from previous research and to rigorously evaluate the efficacy and safety of pridopidine in people living with HD. As investigators, we look forward to working with participating centers and the HD community to generate robust evidence that can help us better understand the potential role of the study treatment in HD,” said Dr. Ralf Reilmann, Principal Investigator and member of the PRECISE-HD Steering Committee.

“For people living with Huntington’s disease and their families, every step toward a better understanding of the disease and potential treatment options matters. We welcome the involvement of European centers in PRECISE-HD and the continued focus on outcomes that reflect the realities and priorities of people living with HD and their families,” said Astri Arnesen, President of the European Huntington Association.

EHDN 2026 Clinical Research Congress

Prilenia and Ferrer will participate at the European Huntington’s Disease Network (EHDN) Clinical Research Congress 2026, taking place October 22–24, 2026, in Kraków, Poland, with Prilenia’s Chief Executive Officer, Dr. Michael R. Hayden, giving an oral presentation on clinical trial design and determination of clinical meaningfulness, in addition to four poster presentations, describing clinically meaningful change in early manifest HD, placebo response in the PROOF-HD clinical trial, and the designs of the PREVAiLS and PRECISE-HD studies of pridopidine in ALS and HD respectively.

[This press release is intended for informational purposes only. Pridopidine is an investigational medicine and is not approved for commercial use by any regulatory authority. Its safety and efficacy have not been established. Information contained herein does not constitute medical advice. Patients should consult their healthcare provider for guidance regarding diagnosis or treatment options. Local regulations may vary; this release is not intended to promote or advertise any product.]

About HD

Huntington’s disease (HD) is a rare, inherited, autosomal dominant, neurodegenerative disease that results in functional, motor, cognitive and behavioral symptoms, and ultimately leads to death. HD is caused by a mutation in the huntingtin (HTT) geneii, and each child of a parent with HD has a 50 percent chance of developing the diseaseiii.

Across the world an estimated 100,000 people have HDiv, with an additional 300,000 people at risk of developing HDv,vi. It is usually diagnosed between the ages of 35 and 55vii viii, although HD can occur at any age, including in children and young adults (known as juvenile onset HD or JHD). The disease progresses slowly over 10 to 30ix years, with patients slowly losing their ability to work, communicate, manage day-to-day life and take care of themselves. This increasing disability leads to full reliance on a caregiver and, ultimately, death.

The only currently available treatments for HD focus on symptomatic relief and palliative care, with no approved therapies shown to impact measures of overall disease progression.

About pridopidine

Pridopidine is an investigational highly selective, oral sigma-1 receptor (S1R) agonist. S1R has been shown to play a role in stimulating multiple neuroprotective pathways impaired in neurodegenerative diseases, such as Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS)x.

In clinical studies to date, pridopidine (taken as an oral capsule twice a day) has shown a generally favorable safety and tolerability profile, with data from more than 1,600 people (mostly from HD studies), some of whom have received active treatment for up to seven yearsxi.

Pridopidine is currently in late-stage clinical development for HD and ALS. It has Orphan Drug Designation in HD and ALS in the US and EU, and FDA Fast Track designation in the US for the treatment of HD. These designations do not imply that pridopidine has been approved or that safety and efficacy have been established.

About the PRECISE-HD Study

PRECISE-HD (Pridopidine Phase 3 Study to Establish Clinical Impact and Safety in Huntington’s Disease) is a confirmatory, global, 400-participant, randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of pridopidine, an investigational medicinal product, in people living with Huntington’s disease (HD), from early to mid-stage disease (TFC 7-13).

Focused on generating data to further support regulatory evaluation, the study will assess the clinical effect of pridopidine on disease progression, functional capacity, motor function, cognition, speech and quality of life. It incorporates learnings from prior research, advice and input from the HD patient and research community, and regulatory authorities.

PRECISE-HD comprises two consecutive stages: a 52-week placebo-controlled stage, with participants randomized to receive either pridopidine or placebo on a 1:1 basis, followed by a 104-week open-label extension stage in which all eligible participants will receive pridopidine. The primary endpoint is the change from baseline to Week 52 in the combined Unified Huntington’s Disease Rating Scale (cUHDRS) score.

PRECISE-HD will be undertaken at up to 75 sites globally, including sites in the United States, European Union, United Kingdom and Canada. Further details are available at clinicaltrials.gov (NCT07609108) and clinicaltrialsregister.eu (2026-526093-16-00).

About Prilenia

Prilenia is a private biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Our mission is simple but urgent: to develop and provide sustainable access to transformative medicines for people affected by devastating neurodegenerative diseases.

Prilenia is incorporated in the Netherlands and backed by leading life sciences investors.

Prilenia and Ferrer are partners in co-development and commercialisation of pridopidine.

For more information, please visit www.prilenia.com, and connect with us on LinkedIn, X or Instagram.

About Ferrer

At Ferrer, we use business to fight for social justice. We have long been a company that wants to do things differently; instead of maximizing shareholder returns, we reinvest much of our profit in initiatives that give back to society. Back where it belongs. We go beyond compliance and are guided by the highest standards of sustainability, ethics and integrity. As such, since 2022, we are a B Corp.

Founded in Barcelona in 1959, Ferrer offers transformative solutions for life-threatening diseases in more than one hundred countries. In line with our purpose, we have an increasing focus on pulmonary vascular and interstitial lung diseases and rare neurological disorders. Our 1,800-strong team is driven by a clear conviction: our business is not an end in itself, but a way to change lives.

We are Ferrer. Ferrer for good. www.ferrer.com

i In April 2025, Prilenia and Ferrer signed a commercialization and co-development agreement for pridopidine. https://news.prilenia.com/press-releases/press-release-details/2025/Prilenia-Enters-into-a-Collaboration-and-License-Agreement-with-Ferrer-for-the-Commercialization-and-Co-Development-of-Pridopidine-in-Europe-and-Other-Select-Markets/default.aspx
ii Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis. 2019 Sep;129:118-129. doi: 10.1016/j.nbd.2019.05.009. Epub 2019 May 17. PMID: 31108174; PMCID: PMC6996243.

iii Myers RH. Huntington’s disease genetics. NeuroRx. 2004 Apr;1(2):255-62. doi: 10.1602/neurorx.1.2.255. PMID: 15717026; PMCID: PMC534940.)

iv Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012 Aug;27(9):1083-91. doi: 10.1002/mds.25075. Epub 2012 Jun 12. PMID: 22692795.

v Medina et al., Prevalence and Incidence of Huntington’s Disease: An Updated Systematic Review and Meta-Analysis. Mov Disord. 2022 Dec;37(12):2327-2335.

vi Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023). From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research. International Journal of Molecular Sciences, 24(16), 13021. https://doi.org/10.3390/ijms241613021
vii EHDN. About Huntington’s Disease. April 2024. Available at: https://ehdn.org/about-hd/ (accessed April 2025).

viii Petracca M, et al. Clinical and genetic characteristics of late-onset Huntington’s disease in a large European cohort. Eur J Neurol. 2022;29:1940–51. ​

ix Mayo Clinic. Huntington’s disease. Available at: https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/symptoms-causes/syc-20356117
x Lachance V, Bélanger S-M, Hay C, Le Corvec V, Banouvong V, Lapalme M, Tarmoun K, Beaucaire G, Lussier MP, Kourrich S. Overview of Sigma-1R Subcellular Specific Biological Functions and Role in Neuroprotection. International Journal of Molecular Sciences. 2023; 24(3):1971. https://doi.org/10.3390/ijms24031971
xi Goldberg YP, Navon-Perry L, Cruz-Herranz A, Chen K, Hecker-Barth G, Spiegel K, Cohen Y, Niethammer M, Tan AM, Schuring H, Geva M, Hayden MR. The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease. CNS Drugs. 2025 May;39(5):485-498. doi: 10.1007/s40263-025-01171-x. Epub 2025 Mar 7. PMID: 40055280; PMCID: PMC11982116.

Contacts

Media Contacts:

Prilenia Contact
Rob Cohen, Head of Corporate Communications

rob.cohen@prilenia.com

Ferrer Contact

Alba Soler, Director of Communication

asolerc@ferrer.com

Bonerge Lifescience to Launch BonFusion™ and BonVesio™ Precision Delivery Platforms at SupplySide Global 2026

Bonerge Lifescience to Launch BonFusion™ and BonVesio™ Precision Delivery Platforms at SupplySide Global 2026




Bonerge Lifescience to Launch BonFusion™ and BonVesio™ Precision Delivery Platforms at SupplySide Global 2026

Preclinical data show 3x higher bioavailability for water-dispersible urolithin A; liposomal S-equol reaches >85% encapsulation efficiency, PDI <0.2


NEW YORK–(BUSINESS WIRE)–#Bioavailability–Bonerge Lifescience today announced BonFusion™ and BonVesio™, two complementary technology platforms designed to address formulation challenges associated with poorly water-soluble nutritional ingredients. The company will introduce the platforms at SupplySide Global 2026 in Las Vegas (October 28–30, Booth 7911-2), showcasing delivery solutions for urolithin A, fisetin and S-equol.

As the nutritional ingredients industry advances, formulation performance is becoming an increasingly important consideration alongside ingredient quality and dosage. Solubility, gastrointestinal stability, absorption and metabolism can all influence how an active compound behaves in the body. Bonerge’s two platforms address these challenges through molecule-specific delivery design and measurable formulation quality attributes.

BonFusion™: A molecule-first approach to delivery design

BonFusion™ evaluates the physicochemical properties and formulation challenges of individual ingredients to guide the selection and integration of complementary delivery technologies. Rather than relying on a single approach for every compound, the platform is designed to accommodate different ingredients and finished-product formats.

For urolithin A and fisetin, BonFusion™ incorporates the ingredients into lipid-based submicron dispersions designed to improve aqueous dispersibility and dissolution performance. Target particle sizes are approximately 200–300 nm, with formulations being developed for applications across capsules, tablets, sachets, oral liquids and beverages.

In a preclinical pharmacokinetic study, BonFusion™ water-dispersible urolithin A demonstrated threefold higher bioavailability than conventional urolithin A powder. These findings support further investigation of the formulation’s potential to improve oral delivery performance.

BonVesio™: Engineering measurable liposomal performance

BonVesio™ specializes in liposomal delivery systems, emphasizing the characterization of critical quality attributes rather than relying on the liposomal designation alone.

One application is BonVesio™ liposomal S-equol. S-equol, a bioactive metabolite of the soy isoflavone daidzein, presents formulation challenges related to its limited aqueous solubility.

The formulation features an encapsulation efficiency above 85%, with a particle size of 100–200 nm and a polydispersity index (PDI) below 0.2. These parameters reflect high encapsulation and a uniform vesicle size distribution, supporting systematic formulation characterization and quality control.

“Delivery performance should be evaluated through measurable parameters and appropriate supporting data,” said Orin Chou, R&D Director of Bonerge Lifescience. “Through BonFusion and BonVesio, we aim to give our partners a more systematic approach to formulation development, from selecting suitable delivery technologies to characterizing the resulting systems.”

Meet Bonerge at SupplySide Global 2026

Bonerge invites supplement brands, formulators and ingredient buyers to visit Booth 7911-2 to explore the two platforms, review supporting formulation data and discuss opportunities for next-generation nutritional products.

About Bonerge Lifescience

Bonerge Lifescience develops functional ingredients and advanced formulation solutions for the global nutrition and dietary supplement industries. Its portfolio spans healthy aging, women’s health, sleep and metabolic wellness, combining ingredient development, formulation technology and clinical research to support next-generation nutritional products.

Contacts

Media Contact
Cecilia Yang

sales@bonerge.com
www.bonerge.com

Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease

Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease




Ferrer and Prilenia Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington’s Disease

BARCELONA, Spain–(BUSINESS WIRE)–Ferreri and Prilenia Therapeutics B.V. today announced that the confirmatory Phase 3 PRECISE-HD study of investigational pridopidine in Huntington’s disease (HD) has received authorization to begin in participating EU Member States (EU CT number: 2026-526093-16-00, NCT07609108). Recruitment in the EU is expected to commence this month, joining currently recruiting sites in the US and UK, with Canada to follow.


Designed to evaluate the efficacy and safety of pridopidine (administered as an oral capsule twice a day), and to generate data for regulatory evaluation, the global, approximately 400-participant, randomized, double-blind, placebo-controlled PRECISE-HD study will assess the clinical effect of the investigational treatment on disease progression, functional capacity, motor function, cognition, speech and quality of life.

“The initiation of PRECISE-HD in Europe marks a milestone for the Huntington’s disease research community. This confirmatory Phase 3 study has been designed to build on learnings from previous research and to rigorously evaluate the efficacy and safety of pridopidine in people living with HD. As investigators, we look forward to working with participating centers and the HD community to generate robust evidence that can help us better understand the potential role of the study treatment in HD,” said Dr. Ralf Reilmann, Principal Investigator and member of the PRECISE-HD Steering Committee.

“For people living with Huntington’s disease and their families, every step toward a better understanding of the disease and potential treatment options matters. We welcome the involvement of European centers in PRECISE-HD and the continued focus on outcomes that reflect the realities and priorities of people living with HD and their families,” said Astri Arnesen, President of the European Huntington Association.

“At Ferrer, putting our purpose into practice also means taking on complex scientific challenges, while recognizing the uncertainty inherent in research. The authorization to initiate PRECISE-HD in participating EU Member States is a further step in our work with Prilenia. We approach that work with a clear sense of responsibility: to conduct research with integrity and let the evidence lead the way,” said Oscar Pérez, Chief Scientific Officer at Ferrer.

About HD

Huntington’s disease (HD) is a rare, inherited, autosomal dominant, neurodegenerative disease that results in functional, motor, cognitive and behavioral symptoms, and ultimately leads to death. HD is caused by a mutation in the huntingtin (HTT) geneii, and each child of a parent with HD has a 50 percent chance of developing the diseaseiii.

Across the world an estimated 100,000 people have HDiv, with an additional 300,000 people at risk of developing HDv,vi. It is usually diagnosed between the ages of 35 and 55vii viii, although HD can occur at any age, including in children and young adults (known as juvenile onset HD or JHD). The disease progresses slowly over 10 to 30ix years, with patients slowly losing their ability to work, communicate, manage day-to-day life and take care of themselves. This increasing disability leads to full reliance on a caregiver and, ultimately, death.

The only currently available treatments for HD focus on symptomatic relief and palliative care, with no approved therapies shown to impact measures of overall disease progression.

About pridopidine

Pridopidine is an investigational highly selective, oral sigma-1 receptor (S1R) agonist. S1R has been shown to play a role in stimulating multiple neuroprotective pathways impaired in neurodegenerative diseases, such as Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS)x.

In clinical studies to date, pridopidine (taken as an oral capsule twice a day) has shown a generally favorable safety and tolerability profile, with data from more than 1,600 people (mostly from HD studies), some of whom have received active treatment for up to seven yearsxi.

Pridopidine is currently in late-stage clinical development for HD and ALS. It has Orphan Drug Designation in HD and ALS in the US and EU, and FDA Fast Track designation in the US for the treatment of HD. These designations do not imply that pridopidine has been approved or that safety and efficacy have been established.

About the PRECISE-HD Study

PRECISE-HD (Pridopidine Phase 3 Study to Establish Clinical Impact and Safety in Huntington’s Disease) is a confirmatory, global, 400-participant, randomized, double-blind, placebo-controlled study designed to further evaluate the efficacy and safety of pridopidine, an investigational medicinal product, in people living with Huntington’s disease (HD), from early to mid-stage disease (TFC 7-13).

Focused on generating data to further support regulatory evaluation, the study will assess the clinical effect of pridopidine on disease progression, functional capacity, motor function, cognition, speech and quality of life. It incorporates learnings from prior research, advice and input from the HD patient and research community, and regulatory authorities.

PRECISE-HD comprises two consecutive stages: a 52-week placebo-controlled stage, with participants randomized to receive either pridopidine or placebo on a 1:1 basis, followed by a 104-week open-label extension stage in which all eligible participants will receive pridopidine. The primary endpoint is the change from baseline to Week 52 in the combined Unified Huntington’s Disease Rating Scale (cUHDRS) score.

PRECISE-HD will be undertaken at up to 75 sites globally, including sites in the United States, European Union, United Kingdom and Canada. Further details are available at www.clinicaltrials.gov (NCT07609108), www.clinicaltrialsregister.eu/ (EU CT number: 2026-526093-16-00).

About Ferrer

At Ferrer, we use business to fight for social justice. We have long been a company that wants to do things differently; instead of maximizing shareholder returns, we reinvest much of our profit in initiatives that give back to society. Back where it belongs. We go beyond compliance and are guided by the highest standards of sustainability, ethics and integrity. As such, since 2022, we are a B Corp.

Founded in Barcelona in 1959, Ferrer offers transformative solutions for life-threatening diseases in more than one hundred countries. In line with our purpose, we have an increasing focus on rare pulmonary and neurological diseases. Our 1,800-strong team is driven by a clear conviction: our business is not an end in itself, but a way to change lives.

We are Ferrer. Ferrer for good. www.ferrer.com

i In April 2025, Prilenia and Ferrer signed a commercialization and co-development agreement for pridopidine. https://news.prilenia.com/press-releases/press-release-details/2025/Prilenia-Enters-into-a-Collaboration-and-License-Agreement-with-Ferrer-for-the-Commercialization-and-Co-Development-of-Pridopidine-in-Europe-and-Other-Select-Markets/default.aspx
ii Eddings CR, Arbez N, Akimov S, Geva M, Hayden MR, Ross CA. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor. Neurobiol Dis. 2019 Sep;129:118-129. doi: 10.1016/j.nbd.2019.05.009. Epub 2019 May 17. PMID: 31108174; PMCID: PMC6996243.

iii Myers RH. Huntington’s disease genetics. NeuroRx. 2004 Apr;1(2):255-62. doi: 10.1602/neurorx.1.2.255. PMID: 15717026; PMCID: PMC534940.)

iv Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov Disord. 2012 Aug;27(9):1083-91. doi: 10.1002/mds.25075. Epub 2012 Jun 12. PMID: 22692795.

v Medina et al., Prevalence and Incidence of Huntington’s Disease: An Updated Systematic Review and Meta-Analysis. Mov Disord. 2022 Dec;37(12):2327-2335.

vi Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023). From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research. International Journal of Molecular Sciences, 24(16), 13021. https://doi.org/10.3390/ijms241613021
vii EHDN. About Huntington’s Disease. April 2024. Available at: https://ehdn.org/about-hd/ (accessed April 2025).

viii Petracca M, et al. Clinical and genetic characteristics of late-onset Huntington’s disease in a large European cohort. Eur J Neurol. 2022;29:1940–51. ​

ix Mayo Clinic. Huntington’s disease. Available at: https://www.mayoclinic.org/diseases-conditions/huntingtons-disease/symptoms-causes/syc-20356117
x Lachance V, Bélanger S-M, Hay C, Le Corvec V, Banouvong V, Lapalme M, Tarmoun K, Beaucaire G, Lussier MP, Kourrich S. Overview of Sigma-1R Subcellular Specific Biological Functions and Role in Neuroprotection. International Journal of Molecular Sciences. 2023; 24(3):1971. https://doi.org/10.3390/ijms24031971
xi Goldberg YP, Navon-Perry L, Cruz-Herranz A, Chen K, Hecker-Barth G, Spiegel K, Cohen Y, Niethammer M, Tan AM, Schuring H, Geva M, Hayden MR. The Safety Profile of Pridopidine, a Novel Sigma-1 Receptor Agonist for the Treatment of Huntington’s Disease. CNS Drugs. 2025 May;39(5):485-498. doi: 10.1007/s40263-025-01171-x. Epub 2025 Mar 7. PMID: 40055280; PMCID: PMC11982116.

Contacts

Ferrer media:

Alba Soler, Director of Communication

asolerc@ferrer.com
Paula Bonet

pbonetg@ferrer.com

Sartorius continues its positive growth and margin trajectory with strong nine-month performance

SARTORIUS Aktiengesellschaft

/ Key word(s): 9 Month figures

Sartorius continues its positive growth and margin trajectory with strong nine-month performance (news with additional features)

22.10.2026 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Göttingen, Germany | October 22, 2026

Sartorius continues its positive growth and margin trajectory with strong nine-month performance
 

  • Growth across both divisions: Lab and bioprocess divisions contribute almost equally to strong sales increase
  • Operational Group sales revenue excluding U.S. tariff compensation to customers grows by 8.1 percent in constant currencies
  • Underlying EBITDA1 margin up 0.5 percentage points to 30.2 percent
  • Management confirms and partially refines full-year guidance for 2026 

 

The life science group Sartorius sustained its positive business trajectory in the first nine months of 2026 and delivered robust growth in sales revenue and profitability. The company also significantly improved its cash flow generation and further reduced its leverage.
 
“Our business continued to develop positively in the first nine months of 2026. The recurring business with consumables remained an important growth driver, while demand for bioprocess equipment and instruments continued to recover. Building on the traction gained in recent quarters and supported particularly by its bioanalytics portfolio, the lab division continued its positive trajectory and showed substantial sales growth. This clearly reinforces our confidence in the full-year guidance for 2026,” said Sartorius CEO Dr. Michael Grosse. “Overall, end markets remain fundamentally healthy, and customer activity continues to be robust. The momentum we are seeing in our lab business is particularly encouraging: Research and drug development activities remain strong, increasingly supported by AI‑driven workflows, and customer pipelines are healthy. Today, we are already benefiting from our strong position in the life science research market, and as new molecules progress through development, this will translate into future opportunities for our bioprocessing business.”

Business development of the Group1

In the first nine months of the fiscal year, Sartorius Group generated sales revenue of 2,737 million euros, with operational sales revenue growing by 8.1 percent in constant currencies compared with the prior-year period. The recurring business with consumables remained the main driver of this development across both divisions. In addition, the non-recurring business with bioprocess equipment and laboratory instruments contributed to growth. MATTEK, the microtissue specialist acquired in July 2025, contributed 0.3 percentage points to the Group’s sales revenue growth.

The business results reported for the first nine months of the year continued to be impacted by a non‑operational effect: In the third quarter, the company received further tariff refunds for levies invalidated by the U.S. Supreme Court. As Sartorius compensates customers for corresponding tariff surcharges previously paid, the related amounts are recognized as reductions in cost of sales and sales revenue. Including the impact from tariff compensation to customers, which amounts to around 31 million euros after the first nine months of 2026, sales revenue grew by 6.9 percent in constant currencies (reported: 4.9 percent).

All regions contributed to the positive business performance: The EMEA region recorded a 6.4 percent gain in constant currencies compared with the prior-year period, achieving 1,155 million euros in sales revenue. The Americas region, which continued to be impacted by U.S. tariff compensation to customers, generated sales revenue of 938 million euros. Excluding the tariff compensation effect, growth amounted to 8.4 percent in constant currencies; including this effect, the increase was 4.9 percent in constant currencies. The Asia/Pacific region grew significantly by 11 percent in constant currencies to 644 million euros, with China contributing positively to regional performance.

The Group’s underlying EBITDA rose by 6.9 percent to 828 million euros in the first nine months of 2026 with the corresponding margin increasing by 0.5 percentage points to 30.2 percent (PY: 29.7 percent). Positive volume development and economies of scale more than offset product mix effects as well as investments in growth initiatives. On a net basis, tariff surcharges and the related customer compensation balanced each other out and had no impact on profitability.

Underlying net profit increased by 6.7 percent to 260 million euros (PY: 244 million euros). Underlying earnings per ordinary share were 3.76 euros (PY: 3.52 euros) and underlying earnings per preference share stood at 3.77 euros (PY: 3.53 euros).

The number of employees at Sartorius Group grew in all regions in the first nine months of the year, primarily due to the hiring of additional production personnel. As of September 30, 2026, the company employed 14,273 people (December 31, 2025: 14,042).

Key financial indicators

Sartorius Group’s balance sheet and key financial indicators improved from robust levels. As of September 30, 2026, the equity ratio increased to 42.8 percent (December 31, 2025: 39.8 percent). As planned, the leverage ratio of net debt to underlying EBITDA was further reduced and reached 3.33 (December 31, 2025: 3.55).

Cash flow from operating activities increased by 9.9 percent to 562 million euros in the first nine months of the current fiscal year (PY: 511 million euros). Key drivers were the positive earnings development and tariff refunds received. Investments in the company’s global research and production infrastructure amounted to 262 million euros in the first nine months of 2026 (PY: 305 million euros). The ratio of capital expenditure to sales revenue stood at 9.6 percent (PY: 11.7 percent). Based on the positive trend in operating cash flow and the lower investment volume, free cash flow increased disproportionately by 55.2 percent to 310 million euros (PY: 200 million euros).

Business development of the Bioprocess Solutions Division

The Bioprocess Solutions Division, which accounts for around 80 percent of Group sales revenue and offers a wide range of innovative technologies for the more efficient and sustainable manufacture of biopharmaceuticals, maintained its profitable growth path in the first nine months of 2026. Sales revenue increased to 2,213 million euros. Excluding the effect from tariff compensation to customers, operational sales revenue growth amounted to 8.1 percent in constant currencies compared with the prior-year period. Including this effect, sales revenue grew by 6.8 percent in constant currencies (reported: 4.6 percent).

The division’s underlying EBITDA increased by 7.1 percent to 714 million euros, with the corresponding margin amounting to 32.3 percent (PY: 31.5 percent). Positive volume effects and economies of scale more than offset dampening product mix effects. On a net basis, tariff surcharges and the related customer compensation balanced each other out and had no impact on profitability.

The Bioprocess Solutions Division introduced several new products in two strategic areas. A single-use bioreactor bag with an improved sparger for better oxygen transfer enables more efficient process intensification in upstream, thereby facilitating adoption of single-use processes in commercial production by helping customers produce higher output from smaller bioreactor volumes. In advanced therapies, the company added ready-to-use cytokines in closed sterile bags and a new animal‑component-free cell culture medium to the portfolio.

Business development of the Lab Products & Services Division

Lab Products & Services, which focuses on life science research and biopharmaceutical laboratories, grew substantially in the first nine months of 2026. Growth was supported by the recurring consumables and services business as well as by instruments, particularly within the bioanalytics portfolio. In the reporting period, the division’s sales revenue increased to 524 million euros, also reflecting some positive effects from pulled-in projects in the third quarter. Excluding the effect from tariff compensation to customers, sales revenue growth amounted to 8.3 percent in constant currencies. Including this effect, sales revenue was up 7.5 percent in constant currencies (reported: 5.9 percent). MATTEK, the microtissue specialist acquired in July 2025, contributed 1.9 percentage points to the division’s sales revenue growth.

The division’s underlying EBITDA grew by 5.6 percent to 114 million euros, compared with 108 million euros in the same period of the previous year. Despite continued investments in growth initiatives, the corresponding margin reached the prior-year’s level of 21.7 percent, supported by positive volume effects and economies of scale. On a net basis, tariff surcharges and the related customer compensation balanced each other out and had no impact on profitability.

The Lab Products & Services Division continued to expand its bioanalytics offering, strengthening its position in increasingly AI-driven drug discovery workflows. Another step in this direction is the enhancement of the established Incucyte live-cell analysis platform with an AI-powered software module that helps researchers to automatically monitor the quality of stem cells, allowing label-free analysis and generating quicker results. In addition, the division introduced a new biosensor for the Octet platform, enabling scientists to measure high antibody levels with less sample preparation and make faster decisions across bioprocessing workflows.

Guidance for fiscal year 2026 confirmed and partially refined

Based on the business performance in the first nine months of 2026 and the continued positive development of the relevant end markets, management confirms its full-year guidance for the Group and the Bioprocess Solutions Division. At the same time, management refines the guidance for the Lab Products & Services Division and the expected ratio of capital expenditure to sales revenue.

Management continues to expect operational sales revenue growth in constant currencies, excluding tariff effects, to be around the midpoint of the respective guidance bandwidths of 5 to 9 percent for the Sartorius Group and 6 to 10 percent for Bioprocess Solutions, while growth in Lab Products & Services is now expected to be around the upper end of its 4 to 6 percent range (previously: upper half). These ranges include a growth contribution from the MATTEK acquisition of approximately 0.3 percentage points at Group level and approximately 1.5 percentage points in Lab Products & Services.

Including the effects from the changed tariff environment and the intended customer compensation for unlawfully imposed U.S. tariffs, which could reduce Group revenue by up to 40 million euros compared with initial assumptions, sales revenue growth in constant currencies is expected to be in the lower half of the guidance range for the Group. Bioprocess Solutions is also expected to be in the lower half of its guidance range, while Lab Products & Services is expected to land around the upper end.

With regard to profitability, management continues to project the Group’s underlying EBITDA margin to increase to slightly above 30 percent, the margin of the Bioprocess Solutions Division to grow slightly above 32 percent and the margin of the Lab Products & Services Division to be slightly above 21 percent (previously: slightly below 21 percent).

The ratio of capital expenditure to sales revenue is now expected to be around 12 percent and thus slightly below the previously expected prior-year level of 12.5 percent. The ratio of net debt to underlying EBITDA should decrease to slightly above 3 (PY: 3.55).

As in previous years, all forecast figures are based on constant currencies. Management notes that industry dynamics and volatility have increased significantly in recent years. In addition, uncertainties resulting from the changed geopolitical environment and related tariff measures continue to play an important role. Consequently, forecasting business performance continues to be subject to a high degree of uncertainty.

New Executive Board responsibilities and reporting structure from 2027

As outlined at the Capital Markets Day in March, Sartorius is continuing to advance the implementation of its updated strategy. To further strengthen its focus on product innovation, customer centricity and operational excellence under its One Sartorius approach, the company has adapted its operating model. Reflecting this new setup, responsibilities within the Executive Board will change from January 1, 2027: Dr. Alexandra Gatzemeyer will assume the role of Chief Commercial Officer, with responsibility for Account Management, Marketing, and Customer and Technical Services across the Group, while Dr. René Fáber, as Chief Product Officer, will be responsible for Research and Development, Product Management, Technical Sales and Manufacturing.

In this context, we are also adjusting our external reporting to align it more closely with the company’s corporate structure and reduce reporting complexity. Effective January 1, 2027, the current Bioprocess Solutions and Lab Products & Services divisions will be replaced by the segments Bioprocessing Solutions and Research Solutions. Bioprocessing Solutions, which provides technologies for biopharmaceutical manufacturing, will exactly mirror Sartorius Stedim Biotech. The Research Solutions segment will fully focus on innovative lab instruments and consumables for research and quality assurance laboratories and will comprise the Group’s businesses outside Sartorius Stedim Biotech.

1 Sartorius publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving the comparability of business performance over time and within the industry. 

  • Underlying EBITDA: earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
  • Underlying net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate
  • Underlying earnings per share: underlying net profit in relation to the weighted-average number of outstanding ordinary or preference shares
  • Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period 

2 EMEA = Europe, Middle East, Africa 

This media release contains forward-looking statements about the future development of the Sartorius Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius assumes no liability for updating such statements in light of new information or future events. This is a translation of the original German-language media release. Sartorius shall not assume any liability for the correctness of this translation. The original German media release is the legally binding version. 

Conference Call for investors

CEO Dr. Michael Grosse and CFO Dr. Florian Funck will discuss the company’s nine-month results in a conference call for investors on October 22, 2026, at 1:00 p.m. CEST.
Register here: https://sar.to/9M_2026_IR_Call

Financial calendar
February 23, 2027 – Full-year figures 2026 and 2026 Annual Report
April 15, 2027 – Annual General Meeting
April 22, 2027 – Q1 quarterly statement January to March 2027
July 22, 2027 – Half-year report January to June 2027
October 21, 2027 – 9M quarterly statement January to September 2027

Key Performance Indicators for the first Nine Months of 2026

  Group Bioprocess Solutions Lab Products & Services
in millions of € unless otherwise specified 9 mon. 
2026
9 mon. 
2025
Δ in % Δ in % cc1 9 mon. 
2026
9 mon. 
2025
Δ in % Δ in % cc1 9 mon. 
2026
9 mon. 
2025
Δ in % Δ in % cc1
Sales Revenue                        
Sales revenue 2,737.2 2,610.5 4.9 8.12 | 6.9 2,213.1 2,115.3 4.6 8.12 |6.8 524.2 495.2 5.9 8.32 |7.5
  • EMEA3
1,155.2 1,084.1 6.6 6.4 948.9 886.6 7.0 6.9 206.3 197.5 4.5 4.2
  • Americas3
937.9 924.8 1.4 8.42 | 4.9 767.5 762.7 0.6 7.82 |4.2 170.4 162.1 5.1 10.82 | 8.3
  • Asia | Pacific3
644.1 601.6 7.1 11.0 496.6 466.0 6.6 10.8 147.5 135.6 8.7 11.6
Results                        
Underlying EBITDA4 827.8 774.2 6.9   714.1 666.5 7.1   113.6 107.7 5.6  
Underlying EBITDA
Margin4 in %
30.2 29.7     32.3 31.5     21.7 21.7    
Underlying net profit5 259.8 243.6 6.7                  
Net profit6 188.3 124.7 51.0                  
Cash flow                        
Cash flow from
operating activities
561.6 511.0 9.9                  
Free cash flow7 310.0 199.7 55.2                  
Financial data per share                        
Earnings
per ordinary share5 in €
3.76 3.52 6.7                  
Earnings
per preference share5 in €
3.77 3.53 6.6                  
Balance Sheet | Financials                        
  Sept. 30,
2026
Dec. 31,
2025
                   
Balance sheet total 9,672.4 9,717.2                    
Equity 4,144.3 3,867.2                    
Equity ratio8 in % 42.8 39.8                    
Net debt 3,679.9 3,741.1                    
Ratio of net debt to underlying EBITDA9 3.33 3.55                    

1 Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period.
2 Operational sales growth before customer compensation for tariff surcharges.
3 According to customers’ location.
4 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items.
5 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.
6 After non-controlling interest.
7 Cash flow from operating activities minus cash flow from investing activities.
8 Equity in relation to the balance sheet total.
9 Quotient of net debt and underlying EBITDA over the past 12 months, including the pro forma amount contributed by acquisitions for this period.

Figures are not audited nor reviewed.

A profile of Sartorius

Sartorius is a leading international partner to biopharmaceutical research and manufacturing. The Lab Products & Services Division focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories in pharmaceutical and biopharmaceutical companies as well as academic research institutions. The Bioprocess Solutions Division supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies. With around 60 production and sales locations worldwide, the Germany-based company has a strong global presence. Sartorius regularly supplements its portfolio with acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3.5 billion euros. More than 14,000 employees are working for customers around the globe.

Visit our newsroom or follow Sartorius on LinkedIn.

Contact
Sven Köpsel
Head of Corporate Communications & IR
+49 151 16852626
sven.koepsel@sartorius.com
 


Additional features:

File: Sartorius continues its positive growth and margin trajectory with strong nine-month performance | Media Release


22.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: SARTORIUS Aktiengesellschaft
Otto-Brenner-Straße 20
37079 Göttingen
Germany
Phone: +49.(0)551-308.0
Fax: +49.(0)551-308.3289
E-mail: info@sartorius.com
Internet: www.sartorius.com
ISIN: DE0007165631, DE0007165607
WKN: 716563, 716560
Indices: MDAX, TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard), Hanover; Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 529900EQV2DY4FOAMU38
EQS News ID: 2419798

 
End of News EQS News Service

2419798  22.10.2026 CET/CEST

BioVersys’ BV100 Phase 2 exploratory data selected for rapid fire and poster presentations at IDWeek 2026

Basel, Switzerland. October 22, 2026, 7.00am CEST

 

 

BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria, announced today its participation at IDWeek 2026, taking place October 21–24, 2026, in Washington, DC.

BioVersys will present efficacy and safety results from the Carbapenem-Resistant Microbiological Modified Intention-to-Treat (micro-CRMITT) population of its Phase 2 BV100 trial, which comprised 26 patients with ventilator-associated bacterial pneumonia (VABP) caused by carbapenem-resistant Acinetobacter baumannii (CRAB). This analysis represents a subset of data from the BV100 Phase 2 trial data published in 2024.

Dr. Marc Gitzinger, Chief Executive Officer of BioVersys, said: “We are pleased to present the latest clinical data on BV100 at IDWeek 2026 and to contribute to the evidence supporting new treatment options for severe, life-threatening infections caused by carbapenem-resistant Acinetobacter baumannii. With BV100 now recruiting patients in its Phase 3 registration trial, we remain focused on advancing BV100 as a potential new treatment option for patients with limited alternatives.”

Presentation Details

Rapid Fire Presentation

Title: Intravenous BV100 (Rifabutin for Infusion) plus Polymyxin B versus Best Available Therapy for Ventilator-Associated Bacterial Pneumonia Suspected or Confirmed due to Carbapenem-Resistant Acinetobacter baumannii: Exploratory Efficacy and Safety Results from a Randomized Phase 2 Trial

Presenter: Andrew F. Shorr, MD, MPH, MBA

Date and Time: Friday, October 23, 2026 | 12:35–12:40 p.m. ET

Poster Presentation (P-401)

Title: Intravenous BV100 (Rifabutin for Infusion) plus Polymyxin B versus Best Available Therapy for Ventilator-Associated Bacterial Pneumonia Suspected or Confirmed due to Carbapenem-Resistant Acinetobacter baumannii: Exploratory Efficacy and Safety Results from a Randomized Phase 2 Trial

Presenting Author: Andrew F. Shorr, MD, MPH, MBA

Date and Time: Saturday, October 24, 2026 | 12:15–1:30 p.m. ET

Location: Poster Hall B-C

Dr. Andrew F. Shorr, MD, MPH, MBA, is the division head for Pulmonary and Critical Care Medicine at Medstar Washington Hospital Center and the Director of the Medical Intensive Care Unit. He is a Professor of Medicine at Georgetown University.

BV100 is currently studied in two clinical trials: the Phase 3 global registration trial, RIV-TARGET and the open-label Phase 2b differentiation trial, RIV-CARE in collaboration with ADVANCE-ID.

Sartorius Stedim Biotech delivers strong operational growth and robust profitability

Sartorius Stedim Biotech SA

/ Key word(s): 9 Month figures

Sartorius Stedim Biotech delivers strong operational growth and robust profitability

22-Oct-2026 / 07:00 CET/CEST


Aubagne, France | October 22, 2026

Sartorius Stedim Biotech delivers strong operational growth and robust profitability

  • Sales revenue including tariff compensation to customers at 2,289 million euros, up 6.5 percent in constant currencies (reported: 4.3 percent); operational sales revenue excluding tariff compensation grows by 7.8 percent in constant currencies
  • Underlying EBITDA¹ of 716 million euros and margin at 31.3 percent; net profit of 277 million euros
  • Business develops in line with expectations: Recurring business remains main driver, with equipment continuing its positive growth trend
  • Management confirms and partially refines guidance for 2026
Sartorius Stedim Biotech, a leading provider of innovative technologies for the manufacture of biologics, sustained its positive business trajectory in the first nine months of 2026 and delivered robust growth in sales revenue and profitability. The period was also marked by a significant improvement in cash flow generation and a further reduction in leverage.

“Our operational and financial performance throughout the first nine months of 2026 remained strong, with robust growth in sales revenue and profitability,” said Dr. René Fáber, CEO of Sartorius Stedim Biotech. “Our recurring business with consumables continued to be the backbone of our business, while we saw further encouraging progress in bioprocessing equipment. This positive development across all regions, underpinned by healthy market fundamentals, leaves us well positioned for the remainder of the year and clearly reinforces our confidence in our full-year guidance for 2026.”  

Business development1

During the first nine months of the fiscal year, Sartorius Stedim Biotech generated sales revenue of 2,289 million euros, with operational sales revenue growing by 7.8 percent in constant currencies compared with the prior-year period. The recurring business with consumables remained the main driver of this development. In addition, business with bioprocess equipment grew compared to the prior-year period.

The business results reported for the first nine months of the year were influenced by a non-operational effect: In the third quarter, the company received further tariff refunds for levies invalidated by the U.S. Supreme Court. As Sartorius Stedim Biotech compensates customers for corresponding tariff surcharges previously paid, the related amounts are recognized as reductions in cost of sales and sales revenue. Including the impact from tariff compensation to customers, which amounts to 28 million euros after the first nine months of 2026, sales revenue grew by 6.5 percent in constant currencies (reported: 4.3 percent).

All regions contributed to the positive business performance: The EMEA2 region recorded a 6.5 percent gain in constant currencies compared with the prior-year period, achieving 982 million euros in sales revenue. The Americas region, which continued to be impacted by tariff compensation to customers, generated sales revenue of 783 million euros. Excluding the tariff compensation effect, growth amounted to 7.6 percent in constant currencies; including this effect, the increase was 3.9 percent in constant currencies. The Asia/Pacific region grew significantly by 10.6 percent in constant currencies to 524 million euros, with China contributing positively to regional performance.

The Group’s underlying EBITDA rose by 4.8 percent to 716 million euros in the first nine months of 2026, with the corresponding margin increasing by 0.2 percentage points to 31.3 percent (PY: 31.1 percent). Positive volume effects and economies of scale more than offset product mix effects. On a net basis, tariff surcharges and the related customer compensation offset each other, with no impact on profitability.

Net profit amounted to 277 million euros (PY: 218 million euros), an increase of 26.7 percent. Underlying net profit increased by 9.4 percent to 350 million euros (PY: 320 million euros). Underlying earnings per share rose to 3.59 euros (PY: 3.28 euros), and earnings per share to 2.84 euros (PY: 2.24 euros).

The number of employees at Sartorius Stedim Biotech grew in all regions in the first nine months of the year, primarily due to the hiring of additional production personnel. As of September 30, 2026, the company employed 10,483 people (December 31, 2025: 10,265).

Sartorius Stedim Biotech introduced several new products designed to meet key customer needs in bioprocessing and advanced therapies. A single-use bioreactor bag with an improved sparger for better oxygen transfer enables more efficient process intensification in upstream, thereby facilitating adoption of single-use processes in commercial production by helping customers produce higher output from smaller bioreactor volumes. In advanced therapies, the company added ready-to-use cytokines in closed sterile bags and a new animal‑component-free cell culture medium to the portfolio.

Key financial indicators

Sartorius Stedim Biotech’s balance sheet and key financial indicators improved further from already very robust levels. As of September 30, 2026, equity amounted to 4,390 million euros, corresponding to an increased equity ratio1 of 54.6 percent (December 31, 2025: 4,126 million euros and 51.7 percent, respectively).

Cash flow from operating activities increased by 11.6 percent to 498 million euros in the first nine months of the current fiscal year (PY: 446 million euros). Key drivers were the positive earnings development and tariff refunds received. Investments in the company’s global research and production infrastructure totaled 232 million euros in the first nine months of 2026 (PY: 276 million euros). The ratio of capital expenditure to sales revenue stood at 10.1 percent (PY: 12.6 percent). Based on the positive trend in operating cash flow and the lower investment volume, free cash flow increased disproportionately by 58.5 percent to 264 million euros (PY: 167 million euros).

Gross debt was 2,310 million euros, while net debt amounted to 2,138 million euros. As planned, the company continued to reduce its ratio of net debt to underlying EBITDA1, which reached 2.26 as of September 30, 2026 (December 31, 2025: 2.38).

Guidance for fiscal year 2026 confirmed and partially refined

Based on the business performance in the first nine months of 2026 and the continued positive development of the relevant end markets, management confirms its sales and profitability guidance for the full year and refines the expected ratio of capital expenditure to sales revenue.

Sartorius Stedim Biotech continues to expect sales revenue growth in constant currencies of around 6 to 10 percent. Operational growth excluding tariff-related effects is expected to be around the midpoint of the range, while growth including the intended customer compensation for unlawfully imposed U.S. tariffs is expected to be in the lower half. Customer compensation could reduce sales revenue by up to 35 million euros compared with initial assumptions.

With regard to profitability, management continues to project the underlying EBITDA margin to increase to slightly above 31 percent.  

The ratio of capital expenditure to sales revenue is now expected to be around 13 percent and thus slightly below the previously expected prior-year level of 13.3 percent. The ratio of net debt to underlying EBITDA should decrease to slightly above 2 (PY: 2.38).

Forecasts have been prepared based on historical information and are consistent with accounting policies. All forecast figures are based on constant currencies, as in past years. Management points out that the dynamics and volatility in the industry have increased significantly in recent years. In addition, uncertainties arising from the changed geopolitical situation, such as emerging decoupling tendencies among various countries as well as changes in trade policy frameworks, are playing a greater role. This results in greater uncertainty when forecasting business figures.

1 Sartorius Stedim Biotech publishes alternative performance measures that are not defined by international accounting standards. These are determined with the aim of improving comparability of business performance over time and within the industry.

  • Constant currencies: figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same exchange rate for the current and the previous period
  • Underlying EBITDA: earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items
  • Underlying net profit: profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, and based on the normalized financial result and the normalized tax rate
  • Underlying earnings per share: underlying net profit in relation to the weighted-average number of shares outstanding
  • Equity ratio: equity in relation to the balance sheet total
  • Ratio of net debt to underlying EBITDA: quotient of net debt and underlying EBITDA over the past 12 months

2 EMEA = Europe, Middle East, Africa
 

This media release contains forward-looking statements about the future development of the Sartorius Stedim Biotech Group. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed or implied by such statements. Sartorius Stedim Biotech assumes no liability for updating such statements in light of new information or future events. Sartorius Stedim Biotech shall not assume any liability for the correctness of this release. The original French press release is the legally binding version.

Conference call for investors

Dr. René Fáber, CEO of the Sartorius Stedim Biotech Group, will discuss the company’s nine-month results in a conference call for investors on October 22, 2026, at 1:00 p.m. CEST.
Register here:  https://sar.to/9M_2026_IR_Call

Financial calendar 
February 23, 2027 – Full-year figures 2026 and 2026 Annual Report
April 13, 2027 – Annual Shareholders’ Meeting
April 22, 2027 – Q1 quarterly statement January to March 2027
July 22, 2027 – Half-year report for January to June 2027
October 21, 2027 – 9M quarterly statement January to September 2027

Unaudited Key Figures for the First Nine Months and Third Quarter of 2026
 

In millions of € unless otherwise specified 9 months 2026 9 months 2025 Δ in % Δ in % cc1
Sales revenue 2,289.2 2,195.3 4.3 7.82 | 6.5
  • EMEA3
982.1 921.3 6.6 6.5
  • Americas3
782.9 781.9 0.1 7.62 | 3.9
  • Asia | Pacific3
524.2 492.1 6.5 10.6
Results        
Underlying EBITDA4 716.0 683.1 4.8  
Underlying EBITDA margin4 in % 31.3 31.1    
Underlying net profit5 349.6 319.5 9.4  
Underlying earnings per share5 in € 3.59 3.28 9.4  
Net profit6 276.6 218.3 26.7  
Earnings per share6 in € 2.84 2.24 26.7  
Cash flow        
Cash flow from operating activities 497.6 445.7 11.6  
Free cash flow7 264.3 166.8 58.5  

 

In millions of € unless otherwise specified Q3 2026 Q3 2025 Δ in % Δ in % cc1
Sales revenue 762.1 705.7 8.0 7.42 | 6.8
  • EMEA3
309.7 296.6 4.4  
  • Americas3
270.6 240.4 12.6  
  • Asia | Pacific3
181.7 168.6 7.8  
Results        
Underlying EBITDA4 237.1 221.1 7.2  
Underlying EBITDA margin4 in % 31.1 31.3    
Underlying net profit5 114.6 91.6 25.1  
Underlying earnings per share5 in € 1.18 0.94 25.1  
Net profit6 95.5 64.2 48.7  
Earnings per share6 in € 0.98 0.66 48.7  

1 Constant currencies: Figures given in constant currencies eliminate the impact of changes in exchange rates by applying the same
exchange rate for the current and the previous period.
2 Operational sales growth before customer compensation for tariff surcharges.

3 According to customers’ locations.
4 Earnings before interest, taxes, depreciation, and amortization and adjusted for extraordinary items.
5 Profit for the period after non-controlling interest, adjusted for extraordinary items and amortization, as well as based on the normalized financial result and the normalized tax rate.
6 After non-controlling interest.

7 Cash flow from operating activities minus cash flow from investing activities.

Figures have been neither audited nor reviewed.


Reconciliation of alternative performance measures
 

Reconciliation between EBIT and underlying EBITDA    
In millions of € 9 months 2026 9 months 2025
EBIT (operating result) 454.3 405.0
Extraordinary items 19.4 43.9
Depreciation & amortization 242.3 234.2
Underlying EBITDA 716.0 683.1

Figures have been neither audited nor reviewed.

Reconciliation between EBIT and underlying net result    
In millions of € 9 months 2026 9 months 2025
EBIT (operating result) 454.3 405.0
Extraordinary items 19.4 43.9
Amortization | IFRS 3 81.9 85.3
Normalized financial result1 –81.0 –101.8
Normalized income tax (26%)2 –123.4 –112.4
Underlying net result after tax 351.2 319.9
Non-controlling interest –1.7 –0.4
Underlying net result after taxes and non-controlling interest 349.6 319.5
Underlying earnings per share in € 3.59 3.28

1 Financial result excluding fair value adjustments of hedging instruments and currency effects relating to financing activities
2 Normalized income tax based on the underlying profit before taxes and amortization

Figures have been neither audited nor reviewed.
 

Ratio of net debt to underlying EBITDA    
In millions of € unless otherwise specified Sept. 30, 20261 Dec. 31, 2025
Gross debt 2,310.4 2,599.3
– Cash and cash equivalents 172.0 426.1
Net debt 2,138.3 2,173.1
     
Underlying EBITDA (12 months) 946.7 913.7
Ratio of net debt to underlying EBITDA 2.26 2.38
     

1 Figures are not audited nor reviewed.
 

Capital expenditures    
In millions of € unless otherwise specified 9 months 2026 9 months 2025
Sales revenue 2,289.2 2,195.3
Capital expenditures 231.9 276.1
Capital expenditures as % of sales revenue 10.1 12.6
     

Figures have been neither audited nor reviewed.

A profile of Sartorius Stedim Biotech 

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications, such as cell and gene therapies, safely, rapidly, and sustainably. The shares of Sartorius Stedim Biotech S.A. are quoted on Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In 2025, the company generated sales revenue of around 3 billion euros. More than 10,200 employees work for customers around the globe.

Visit our newsroom or follow Sartorius on LinkedIn.

Contact  
Sven Köpsel
Head of Corporate Communications & IR
+49 151 16852626
sven.koepsel@sartorius.com
 


Attachment

File: Sartorius Stedim Biotech delivers strong operational growth and robust profitability | Media Release


Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.



2419882  22-Oct-2026 CET/CEST

Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study

Newron Pharmaceuticals S.p.A.

/ Key word(s): Study

Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study

22.10.2026 / 07:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Newron Completes Enrollment of Pivotal Phase 3 ENIGMA-TRS 1 Study

Total of 618 patients randomized

Topline 12-week data expected in Q1 2027 

Milan, Italy, and Morristown, NJ, USA – October 22, 2026, 07:00 am CEST – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has completed enrollment in the pivotal Phase 3 ENIGMA-TRS 1 study evaluating evenamide, its proprietary investigational first-in-class glutamate modulator, as a potential first add-on therapy to second-generation antipsychotics in patients meeting established international consensus criteria for treatment-resistant schizophrenia (TRS). A total of 618 patients have been enrolled at more than 80 study centers in 19 countries across Europe, Asia, Latin America and Canada.

Newron expects to disclose topline 12-week data in Q1 2027. The study will continue under double-blind, placebo-controlled conditions through 52 weeks.

“Reaching this important milestone in the ENIGMA-TRS 1 study reflects the tremendous commitment of investigators and clinical teams, alongside the close collaboration of our academic and regulatory partners, as well as the patients and their families. The study is particularly important given the complexity of conducting a first long-term, randomized, double-blind, placebo-controlled add-on study in patients with TRS, an area of considerable unmet medical need.”

“Of the 996 patients who entered screening, 618 were found to be eligible for the study and were randomized to receive evenamide at 15 mg or 30 mg twice daily, or placebo, following strict adherence to the eligibility criteria by the Independent Eligibility Assessment Committee and five CRO psychiatrists. We look forward to continuing working closely with the investigators and their teams towards successful completion of the study”, said Ravi Anand, MD, Chief Medical Officer of Newron.

Evenamide targets the modulation of excessive release of glutamate in patients suffering from treatment-resistant schizophrenia (TRS).
 

About ENIGMA-TRS

ENIGMA-TRS 1 is an ongoing, international, 52-week, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics, including clozapine, were required to meet Treatment Response and Resistance Psychosis international consensus criteria for TRS. The study has completed enrollment, with a total of 618 patients enrolled at study centers in 19 countries in Europe, Asia, Latin America, and Canada.

The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue to be double-blind and placebo-controlled until the 26- and 52-week time points. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce results from the 12-week primary endpoint assessment in Q1 2027.

ENIGMA-TRS 2 is enrolling patients at study centers in Asia and Latin America, with additional sites planned in Europe. The study uses the same screening procedure as ENIGMA-TRS 1. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase 3 study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide compared to placebo. The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. The FDA clinical hold remains in place at U.S. study centers, where no patients have received evenamide.

About Newron Pharmaceuticals

Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently being developed in the global pivotal ENIGMA-TRS Phase 3 program. Clinical trial results to date demonstrate the benefits of this drug candidate in TRS as well as in poorly responding patient populations, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide, has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn.

For more information, please contact:

Newron
Stefan Weber – CEO; pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com  

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
John Fraunces, LifeSci Advisors; +1 917 355 2395, jfraunces@lifesciadvisors.com
 

Important Notices

This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.


22.10.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Newron Pharmaceuticals S.p.A.
via Antonio Meucci 3
20091 Bresso
Italy
Phone: +39 02 610 3461
Fax: +39 02 610 34654
E-mail: pr@newron.com
Internet: www.newron.com
ISIN: IT0004147952
WKN: A0LF18
Listed: Regulated Unofficial Market in Dusseldorf (Primärmarkt); SIX
LEI Code: 8156002F8C11F80A9740
EQS News ID: 2419974

 
End of News EQS News Service

2419974  22.10.2026 CET/CEST